Capturing origins and early adaptive processes underlying therapy response to cancer treatments

Cancer
Credit: Unsplash/CC0 Public Domain

A team of researchers with biotechnology corporation Genentech Inc., has developed a new way to capture the origins and early adaptive processes that are involved in therapy responses to cancer treatments. In their paper published in the journal Nature Biotechnology, the group describes how their new system can be used to help treat resistant types of cancer.

As the researchers note, the current approach to treating patients with is to give them therapies that their doctor believes are best suited to the kind of cancer they have and then watching to see how well it works—and then modifying the approach if the outcome is less than hoped due to resistance. To improve the process, the team has developed a system that is able to take into account pre-existing features of cancer and the changes that might have come about because of them that could lead to treatment resistance. The new system, called TraCe-seq involves analyzing clonal responses to various treatments applied to mutated lung cancer cells—using a single-cell RNA sequencing method. As part of its development, the researchers used EGFR-targeting therapies, which included that have been shown to disrupt enzyme binding.

The researchers note that the system is reliant on combinations of different cellular barcoding along with sequential single-cell sequencing. The bar-coding, they further note, allows for using clonal fitness with untreated cells along with those that are exposed to a variety of different therapies. It was created as a way to provide the best type of available in resistant cases, without having to go through a long trial and error process. By taking into account the genetic history of the cells as they have mutated, the system is able to accurately predict which sorts of therapy will work best at stopping its growth.

Testing of the system showed it capable of providing more pronounced treatment fitness in lung cancers treated with GNE-104 or EGFR inhibitors than cells treated with more traditional options. They suggest the new system is likely just the first of many that will be developed along similar lines—all with the goal of better predicting which therapies will work best on different types of resistant cancers.


Explore further

Novel therapy shows promise for lung cancer patients with rare EGFR mutation

More information: Matthew T. Chang et al, Identifying transcriptional programs underlying cancer drug response with TraCe-seq, Nature Biotechnology (2021). DOI: 10.1038/s41587-021-01005-3
Journal information: Nature Biotechnology

© 2021 Science X Network

Citation: Capturing origins and early adaptive processes underlying therapy response to cancer treatments (2021, September 17) retrieved 18 October 2021 from https://medicalxpress.com/news/2021-09-capturing-early-underlying-therapy-response.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
115 shares

Feedback to editors